Brave science for brave patients

At Athenex Oncology, we believe that science is always in the service of patients. Our unique, investigational scientific platforms are designed to improve and transform cancer therapies by addressing specific limitations. By rethinking the challenges associated with certain cancer treatments, we can help expand the range of treatment options available for the patients who need it the most.

Athenex Oncology’s scientific platforms

ORASCOVERY: OPTIMIZING CHEMOTHERAPY TO HELP IMPROVE OUTCOMES

Intravenous (IV) chemotherapy has significant limitations

  • IV therapy is invasive, time-consuming, and burdensome for patients with cancer
  • Adverse effects such as chemotherapy-induced peripheral neuropathy can lead to dose reductions or discontinuation of therapy, potentially affecting outcomes and quality of life
  • Some chemotherapy agents require administration of steroids prior to therapy to address infusion-related reactions
  • The potential to deliver IV chemotherapy agents orally is limited due to P-glycoprotein (P-gp) activity in the gastrointestinal (GI) tract, which inhibits absorbed drugs that are substrates of P-gp

Inhibition of P-gp in the GI tract improves the absorption of chemotherapy agents that are substrates of P-gp

  • The Orascovery platform may help overcome the limitations of oral chemotherapy by including the administration of encequidar (formerly HM30181A), a P-gp inhibitor, prior to therapy
  • Inhibition of P-gp in the GI tract improves absorption of P-gp substrate chemotherapy agents, achieving systemic exposure profiles that may enhance efficacy and reduce toxicity
  • Oral administration would avoid adverse reactions associated with Cremophor EL, which is a solubilizing agent used in the formulation of IV paclitaxel*

Orascovery with P-gp inhibition may help overcome limitations associated with IV administration of certain chemotherapies, such as dosing, tolerability, and efficacy

*Cremophor EL is also known as Kolliphor® EL, which a registered trademark of BASF Corp.
SRC KINASE INHIBITION: EVOLVING TREATMENT FOR ACTINIC KERATOSIS (AK)
PEGYLATED GENETICALLY-MODIFIED HUMAN ARGINASE: ARGININE DEPRIVATION THERAPY
T-CELL RECEPTOR-ENGINEERED T CELLS (TCR-T): POTENT AND SELECTIVE DIRECT RESPONSE